Dr. Memarzadeh on p53 Reactivation in Ovarian Cancer

In Partnership With:

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

There are 3 approaches that are being taken to restore p53 function. Many of these approaches are focused on restoring p53 folding, Memarzadeh says. It has to be a tetramer and properly folded, so that it can bind to DNA. APR-246 is 1 of the first drugs being tested. The drug was found in a drug screen specifically targeting cells that carry a type of p53 mutation. The compound, states Memarzadeh, has to be converted to methylene quinuclidinone. It then binds to cystines in either p53 or any molecule that carries a cystine. By doing so, it is thought to restore the folding and subsequent function of p53.

This is being tested in clinical trials in combination with other agents. The exact mechanism of action is unknown, states Memarzadeh, which underscores the need for biomarkers of response.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content